Sonia Prieto Martín-Gil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sonia Prieto Martín-Gil has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Antonio J. Martín-Galiano
Proteomics Unit Central Core Facilities, Instituto de Salud Carlos III, Madrid, Spain
2 shared publications - Astrid Pérez
Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
2 shared publications - Michael J. McConnell
Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556, USA
2 shared publications Alberto Peláez-García
Proteomics Unit Central Core Facilities, Instituto de Salud Carlos III, Madrid, Spain
1 shared publicationAna Tajuelo
Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
1 shared publication- Ana Tajuelo
Laboratorio de Infecciones Intrahospitalarias, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Spain
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Nature Communications
A multivalent OMV vaccine induces broad protection against major Klebsiella pneumoniae disease-causing serotypes
- 2 November 2026
- Published by Springer Nature in Nature Communications
Open AccessA multivalent OMV vaccine induces broad protection against major Klebsiella pneumoniae disease-causing serotypes
- Open Access
- 18 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6398
Immunogenic Profiling Reveals Promising RV-Identified Antigens as Vaccine Candidates Against Klebsiella pneumoniae
Multidrug-resistant Klebsiella pneumoniae is an increasing global threat, and the limited availability of new antibiotics highlights vaccination as a promising strategy for infection prevention. Although different vaccine candidates have been evaluated, none is currently approved, mainly due to capsular heterogeneity among strains. Protein-based vaccines may overcome this limitation by targeting conserved epitopes. In this study, we assessed the immunogenicity of five outer membrane proteins (ChiP, LamB, RafY, OmpW, PagP) previously selected by reverse vaccinology (RV), comparing them with the well-characterized antigens OmpA and OmpK36. Mice were immunized intramuscularly with three doses of purified recombinant proteins, and antibody responses were analyzed by ELISA. All antigens elicited high, booster-induced IgG levels, with PagP slightly being less immunogenic. Regarding IgG subclasses, IgG1 predominated, followed by IgG2b and IgG2c. Cross-reactivity was evaluated against six K. pneumoniae strains representing different clonal groups, and recognition by sera from previously infected mice was also examined. OmpA, ChiP and LamB showed the broadest cross-reactivity, while OmpA and LamB were most strongly recognized after infection. Overall, OmpA, LamB, ChiP and RafY emerged as the most promising vaccine candidates, although further optimization, such as a multicomponent vaccine, may be required. This work also highlights the importance of experimentally validating RV-selected antigens, as computational predictions alone do not ensure immunogenicity or in vivo relevance.
- 18 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6398
Open AccessImmunogenic Profiling Reveals Promising RV-Identified Antigens as Vaccine Candidates Against Klebsiella pneumoniae
Multidrug-resistant Klebsiella pneumoniae is an increasing global threat, and the limited availability of new antibiotics highlights vaccination as a promising strategy for infection prevention. Although different vaccine candidates have been evaluated, none is currently approved, mainly due to capsular heterogeneity among strains. Protein-based vaccines may overcome this limitation by targeting conserved epitopes. In this study, we assessed the immunogenicity of five outer membrane proteins (ChiP, LamB, RafY, OmpW, PagP) previously selected by reverse vaccinology (RV), comparing them with the well-characterized antigens OmpA and OmpK36. Mice were immunized intramuscularly with three doses of purified recombinant proteins, and antibody responses were analyzed by ELISA. All antigens elicited high, booster-induced IgG levels, with PagP slightly being less immunogenic. Regarding IgG subclasses, IgG1 predominated, followed by IgG2b and IgG2c. Cross-reactivity was evaluated against six K. pneumoniae strains representing different clonal groups, and recognition by sera from previously infected mice was also examined. OmpA, ChiP and LamB showed the broadest cross-reactivity, while OmpA and LamB were most strongly recognized after infection. Overall, OmpA, LamB, ChiP and RafY emerged as the most promising vaccine candidates, although further optimization, such as a multicomponent vaccine, may be required. This work also highlights the importance of experimentally validating RV-selected antigens, as computational predictions alone do not ensure immunogenicity or in vivo relevance.